AR022672A1 - Una composicion farmaceutica en forma de tabletas o capsulas que constituyen un metodo de administracion oral de una droga - Google Patents

Una composicion farmaceutica en forma de tabletas o capsulas que constituyen un metodo de administracion oral de una droga

Info

Publication number
AR022672A1
AR022672A1 ARP990104682A ARP990104682A AR022672A1 AR 022672 A1 AR022672 A1 AR 022672A1 AR P990104682 A ARP990104682 A AR P990104682A AR P990104682 A ARP990104682 A AR P990104682A AR 022672 A1 AR022672 A1 AR 022672A1
Authority
AR
Argentina
Prior art keywords
drug
pharmaceutical composition
tablets
ciprofloxacin
capsule
Prior art date
Application number
ARP990104682A
Other languages
English (en)
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/152,932 external-priority patent/US6261601B1/en
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of AR022672A1 publication Critical patent/AR022672A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Abstract

Una composicion farmacéutica en forma de tabletas o cápsulas proporciona una combinacion de control temporal y espacial de administracion de droga a unpaciente para lograr resultados terapéuticos efectivos. La composicion farmacéutica comprende unad roga, un componente generador de gas, un agente dilatador,un agente viscosante y, optativamente, un polímero geleficante. El agente dilatador pertenece a una clase de compuestos conocidos como superdesintegradores(por ejemplo, polivinilpirrolidonade enlace cruzado o carboximetilcelulosa sodica). El agente viscosante inicialmente y, luego, el polímero gelificante,forman una matriz de gel hidratado que atrapa el gas, haciendo que la tableta o cápsula flote de manera que quede retenida en elestom ago o en la partesuperior del intestino delgado (control espacial). Al mismo tiempo, la matriz de gel hidratado forma una trayectoria de difusion tortuosa para la droga, lo queresulta en una liberacion sostenida de la droga (control temporal).Una fo rmulacion preferida de ciprofloxacina de una sola administracion diaria comprende69,9% base de ciprofloxacina, 0,34% de alginato de sodio, 1,03% de goma xántica, 13,7% de bicarbonato de sodio, 12,1% de polivinilpirrolidona de enlace cruzadoy,optativ amente, otros excipientes farmacéuticos, estando la formulacion preparada en forma de tableta recubierta o no recubierta o de cápsula.
ARP990104682A 1998-09-14 1999-09-17 Una composicion farmaceutica en forma de tabletas o capsulas que constituyen un metodo de administracion oral de una droga AR022672A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/152,932 US6261601B1 (en) 1997-09-19 1998-09-14 Orally administered controlled drug delivery system providing temporal and spatial control

Publications (1)

Publication Number Publication Date
AR022672A1 true AR022672A1 (es) 2002-09-04

Family

ID=22545063

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990104682A AR022672A1 (es) 1998-09-14 1999-09-17 Una composicion farmaceutica en forma de tabletas o capsulas que constituyen un metodo de administracion oral de una droga

Country Status (41)

Country Link
EP (2) EP1107741B1 (es)
JP (1) JP2002524494A (es)
CN (1) CN1186013C (es)
AP (1) AP1659A (es)
AR (1) AR022672A1 (es)
AT (1) ATE245414T1 (es)
AU (1) AU758324B2 (es)
BG (1) BG105339A (es)
BR (1) BR9913696A (es)
CA (1) CA2343760A1 (es)
CO (1) CO5130022A1 (es)
CU (1) CU23040A3 (es)
CZ (1) CZ2001901A3 (es)
DE (1) DE69909801T2 (es)
DK (1) DK1107741T3 (es)
EA (2) EA005767B1 (es)
EE (1) EE200100153A (es)
ES (1) ES2204098T3 (es)
GE (1) GEP20043216B (es)
HK (1) HK1037967A1 (es)
HR (1) HRP20010187B1 (es)
HU (1) HUP0103632A3 (es)
ID (1) ID29843A (es)
IL (1) IL141977A0 (es)
IS (1) IS5885A (es)
MX (1) MXPA01002634A (es)
MY (1) MY127952A (es)
NO (1) NO20011276L (es)
NZ (2) NZ523747A (es)
OA (1) OA11652A (es)
PE (1) PE20001058A1 (es)
PL (1) PL346798A1 (es)
PT (1) PT1107741E (es)
SI (1) SI1107741T1 (es)
SK (1) SK285478B6 (es)
SV (1) SV1999000152A (es)
TR (1) TR200100731T2 (es)
UA (1) UA73287C2 (es)
UY (1) UY25710A1 (es)
WO (1) WO2000015198A1 (es)
ZA (1) ZA995839B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12381A (en) * 2000-03-03 2004-09-06 Ranbaxy Lab Ltd Orally administered controlled delivery system foronce daily administration of ciprofloxacin.
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
AU2006202275A1 (en) * 2000-06-26 2006-06-22 Bayer Healthcare Ag Sustained-release preparations of quinolone antibiotics and method for preparation thereof
MXPA03001206A (es) 2000-08-08 2003-06-30 Daiichi Pharmaceutical Co Ltd Preparacion solida altamente absorbible.
IN192748B (es) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
WO2002045695A2 (en) 2000-12-05 2002-06-13 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
BR0211317A (pt) * 2001-07-04 2004-12-14 Sun Pharmaceutical Ind Ltd Sistema para a liberação controlada de uma droga por meio de retenção gástrica
JP2005501097A (ja) * 2001-08-16 2005-01-13 ザ ステイト オブ オレゴン アクティング バイ アンド スルー ザ ステイト ボード オブ ハイアー エデュケイション、 オン ビハーフ オブ オレゴン ステイト ユニバーシティー 膨張可能な胃内滞留装置
WO2003017981A1 (en) * 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
CA2466032A1 (en) * 2001-10-29 2003-05-08 Laure Patricia Ouadji Njiki Methods and dosage forms for improving the bioavailability of therapeutic agents
PL374280A1 (en) * 2001-11-13 2005-10-03 Yamanouchi Pharma Technologies, Inc. Soluble drug extended release system
US8192755B2 (en) 2001-11-19 2012-06-05 Lupin Limited Pharmaceutical composition for controlled release of a beta-lactam antibiotic
MXPA04010436A (es) * 2002-04-23 2005-05-27 Lupin Ltd Composiciones de accion a largo plazo que comprenden zidovudina y lamivudina.
WO2005018613A1 (de) * 2003-08-26 2005-03-03 Mandapro Ag Pellets für die orale applikation von pharmazeutischen wirkstoffen
DE102004042139B4 (de) * 2004-08-31 2009-06-10 Aristocon Verwaltungs- Gmbh Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit
GB0501810D0 (en) * 2005-01-28 2005-03-09 Pharmakodex Ltd Chemotherapeutic formulations
EP1912628A2 (en) * 2005-06-29 2008-04-23 Panacea Biotec Ltd. Pharmaceutical sustained release compositions and processes thereof
DE602005007205D1 (de) * 2005-07-19 2008-07-10 Ethypharm Sa Gastroretentive Zusammensetzungen und Verfahren zur Herstellung
GB0515492D0 (en) * 2005-07-28 2005-08-31 Reckitt Benckiser Healthcare Improvements in or relating to compositions,articles and methods
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
ZA200903854B (en) * 2008-06-19 2011-02-23 Univ Of The Witwatesrand Johannesburg A gastroretentive pharmaceutical dosage form
JP2012500230A (ja) 2008-08-18 2012-01-05 北京天衡▲薬▼物研究院 胃内滞留薬物放出システム及びその製造方法と使用
WO2011125075A2 (en) 2010-04-08 2011-10-13 Fdc Limited A novel gastroretentive delivery of macrolide
EP2415460A1 (de) * 2010-08-03 2012-02-08 ratiopharm GmbH Orale Darreichungsform von Pregabalin
TWI705814B (zh) * 2014-06-20 2020-10-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
US11504324B2 (en) 2014-11-19 2022-11-22 DuPont Nutrition USA, Inc. Nanosuspension formulation
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
CN110996922A (zh) 2017-06-16 2020-04-10 卡希夫生物科学有限责任公司 用于持续药物递送的胃滞留剂型
US11229606B2 (en) 2018-06-18 2022-01-25 Amneal Complex Products Research Llc Extended release compositions comprising pyridostigmine
JP7034343B2 (ja) 2018-06-27 2022-03-11 アムニール コンプレックス プロダクツ リサーチ エルエルシー 自己調節性の浸透性胃保持性薬物送達システム
CN110448535A (zh) * 2019-09-04 2019-11-15 湖南宇山玉月农业科技有限公司 一种裂褶菌素胃漂浮片
CN111116794A (zh) * 2019-12-20 2020-05-08 蚌埠市鑫晟新材料科技有限公司 一种中性造纸用聚合材料的制备方法
CN115715765A (zh) * 2021-08-24 2023-02-28 江苏万邦生化医药集团有限责任公司 一种悬浮片剂
CN113768898A (zh) * 2021-09-14 2021-12-10 江苏万邦生化医药集团有限责任公司 悬浮的胶囊片

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0798742B2 (ja) * 1986-07-03 1995-10-25 ゼリア新薬工業株式会社 徐放性製剤組成物
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤

Also Published As

Publication number Publication date
ID29843A (id) 2001-10-18
SK285478B6 (sk) 2007-02-01
MXPA01002634A (es) 2002-06-04
EE200100153A (et) 2002-06-17
AP2001002098A0 (en) 2001-03-31
OA11652A (en) 2004-12-08
EA005767B1 (ru) 2005-06-30
CO5130022A1 (es) 2002-02-27
CN1325299A (zh) 2001-12-05
NZ510487A (en) 2003-04-29
JP2002524494A (ja) 2002-08-06
ZA995839B (en) 2000-03-28
ATE245414T1 (de) 2003-08-15
SV1999000152A (es) 2000-07-03
CN1186013C (zh) 2005-01-26
SK3472001A3 (en) 2001-10-08
ES2204098T3 (es) 2004-04-16
GEP20043216B (en) 2004-04-26
EA004443B1 (ru) 2004-04-29
BG105339A (en) 2001-11-30
SI1107741T1 (en) 2004-02-29
EP1107741A1 (en) 2001-06-20
EP1281397A1 (en) 2003-02-05
HRP20010187B1 (en) 2004-04-30
EP1107741B1 (en) 2003-07-23
PL346798A1 (en) 2002-02-25
MY127952A (en) 2007-01-31
AP1659A (en) 2006-09-06
IS5885A (is) 2001-03-12
PE20001058A1 (es) 2000-10-05
HUP0103632A2 (hu) 2002-02-28
IL141977A0 (en) 2002-03-10
DE69909801D1 (de) 2003-08-28
HUP0103632A3 (en) 2005-06-28
NO20011276D0 (no) 2001-03-13
HK1037967A1 (en) 2002-03-01
CA2343760A1 (en) 2000-03-23
WO2000015198A1 (en) 2000-03-23
HRP20010187A2 (en) 2002-04-30
TR200100731T2 (tr) 2001-06-21
EA200100346A1 (ru) 2001-10-22
DE69909801T2 (de) 2004-06-03
BR9913696A (pt) 2001-10-09
NO20011276L (no) 2001-05-10
CZ2001901A3 (cs) 2001-08-15
PT1107741E (pt) 2003-12-31
UA73287C2 (en) 2005-07-15
DK1107741T3 (da) 2003-11-17
AU1779499A (en) 2000-04-03
CU23040A3 (es) 2005-04-14
AU758324B2 (en) 2003-03-20
NZ523747A (en) 2004-04-30
UY25710A1 (es) 2000-03-31
EA200300847A1 (ru) 2003-12-25

Similar Documents

Publication Publication Date Title
AR022672A1 (es) Una composicion farmaceutica en forma de tabletas o capsulas que constituyen un metodo de administracion oral de una droga
YU19501A (sh) Sistem za kontrolisano davanje lekova oralnim putem koji obezbeđuje vremensku i prostornu kontrolu
KR100890180B1 (ko) 경구투여제 및 경구투여제 유지체
IL143375A0 (en) Sustained release matrix systems for highly soluble drugs
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
DE60310039D1 (de) Pharmazeutische tablette
KR20060135052A (ko) 경구투여제
EP0966966A3 (en) Nefazodone dosage form
MY144021A (en) Pharmaceutical delivery system
JP2007254340A (ja) 経口投与剤
CN113476421A (zh) 一种非布司他的控释组合物及其制备方法
HN2001000038A (es) Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina
ES2194618T1 (es) Composicion oralmente desintegrable que comprende mirtazapina.
RU2005105302A (ru) Композиция бицифадина
ECSP993138A (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
WO2016137266A2 (ko) 에페리손과 펠루비프로펜을 함유하는 약제학적 조성물
ES2572180T3 (es) Formulaciones de liberación controlada que comprenden unidad(es) discreta(s) sin recubrimiento y una matriz de liberación prolongada
JP4527942B2 (ja) 粘膜粘着性活性物質賦形剤の放出用の胃液耐性デバイス、およびこの胃液耐性デバイスの製造方法
AR018041A1 (es) Formulaciones de tiagabina de liberacion prolongada, encapsulada y en comprimidos
DE60219965D1 (de) Lang wirkende zusammensetzungen enthaltend zidovudine und/oder lamivudine
TH50543A3 (th) ระบบการนำส่งยาที่ควบคุมได้สำหรับให้ทางปากซึ่งให้การควบคุมเกี่ยวกับเวลาและบริเวณ
UY28579A1 (es) Formulaciones farmacéuticas transdermicas
NZ513416A (en) Pill dough formulation

Legal Events

Date Code Title Description
FA Abandonment or withdrawal